Comparison of post-COVID-19 symptoms in patients infected with the SARS-CoV-2 variants delta and omicron-results of the Cross-Sectoral Platform of the German National Pandemic Cohort Network (NAPKON-SUEP).

Health-related quality of life Multicenter prospective cohort study Post-covid-19 condition SARS-CoV-2 variants

Journal

Infection

ISSN: 1439-0973

Titre abrégé: Infection

Pays: Germany

ID NLM: 0365307

Informations de publication

Date de publication:
03 May 2024

Historique:

received: 08 01 2024

accepted: 13 04 2024

medline: 3 5 2024

pubmed: 3 5 2024

entrez: 3 5 2024

Statut: aheadofprint

Résumé

The influence of new SARS-CoV-2 variants on the post-COVID-19 condition (PCC) remains unanswered. Therefore, we examined the prevalence and predictors of PCC-related symptoms in patients infected with the SARS-CoV-2 variants delta or omicron. We compared prevalences and risk factors of acute and PCC-related symptoms three months after primary infection (3MFU) between delta- and omicron-infected patients from the Cross-Sectoral Platform of the German National Pandemic Cohort Network. Health-related quality of life (HrQoL) was determined by the EQ-5D-5L index score and trend groups were calculated to describe changes of HrQoL between different time points. We considered 758 patients for our analysis (delta: n = 341; omicron: n = 417). Compared with omicron patients, delta patients had a similar prevalence of PCC at the 3MFU (p = 0.354), whereby fatigue occurred most frequently (n = 256, 34%). HrQoL was comparable between the groups with the lowest EQ-5D-5L index score (0.75, 95% CI 0.73-0.78) at disease onset. While most patients (69%, n = 348) never showed a declined HrQoL, it deteriorated substantially in 37 patients (7%) from the acute phase to the 3MFU of which 27 were infected with omicron. With quality-controlled data from a multicenter cohort, we showed that PCC is an equally common challenge for patients infected with the SARS-CoV-2 variants delta and omicron at least for the German population. Developing the EQ-5D-5L index score trend groups showed that over two thirds of patients did not experience any restrictions in their HrQoL due to or after the SARS-CoV-2 infection at the 3MFU. The cohort is registered at ClinicalTrials.gov since February 24, 2021 (Identifier: NCT04768998).

Identifiants

DOI: 10.1007/s15010-024-02270-5 PMID: 38700656

pubmed: 38700656

doi: 10.1007/s15010-024-02270-5

pii: 10.1007/s15010-024-02270-5

doi:

Banques de données

ClinicalTrials.gov

['NCT04768998']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Public health England. investigation of novel SARS-COV-2 variant - variant of concern 202012/01. 2020. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959438/Technical_Briefing_VOC_SH_NJL2_SH2.pdf . Accessed 2023-02-05.

Yang W, Shaman J. COVID-19 pandemic dynamics in India, the SARS-CoV-2 delta variant, and implications for vaccination. medRxiv. 2021. https://doi.org/10.1101/2021.06.21.21259268 .

doi: 10.1101/2021.06.21.21259268 pubmed: 34909789 pmcid: 8669856

GISAID. Tracking of variants. 2021. https://gisaid.org/hcov19-variants/ . Accessed 2023-02-05.

Robert Koch Institute. Wöchentlicher Lagebericht des RKI zur Coronavirus-Krankheit-(2019) (COVID-19): 05.08.2021—aktualisierter Stand für Deutschland. 2021. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Wochenbericht/Wochenbericht_2021-08-05.pdf?__blob=publicationFile . Accessed 5 Feb 2023.

Robert Koch Institute. Wöchentlicher Lagebericht des RKI zur Coronavirus-Krankheit-2019 (COVID-19): 07.10.2021–AKTUALISIERTER STAND FÜR DEUTSCHLAND. (2021). https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Wochenbericht/Wochenbericht_2021-10-07.pdf?__blob=publicationFile . Accessed 5 Feb 2023.

Hu J, Peng P, Cao X, et al. Increased immune escape of the new SARS-CoV-2 variant of concern Omicron. Cell Mol Immunol. 2022;19:293–5. https://doi.org/10.1038/s41423-021-00836-z .

doi: 10.1038/s41423-021-00836-z pubmed: 35017716 pmcid: 8749347

Robert Koch Institute. SARS-CoV-2 Varianten in Deutschland - Daten aus der integrierten genomischen Surveillance von SARS-CoV-2. (2023). https://public.data.rki.de/t/public/views/IGS_Dashboard/DashboardVOC?%3Aembed=y&%3AisGuestRedirectFromVizportal=y .

Nyberg T, Twohig KA, Harris RJ, et al. Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis. BMJ. 2021. https://doi.org/10.1136/bmj.n1412 .

doi: 10.1136/bmj.n1412 pubmed: 34407988 pmcid: 8372196

Bager P, Wohlfahrt J, Fonager J, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. Lancet Infect Dis. 2021;21:1507–17. https://doi.org/10.1016/S1473-3099(21)00290-5 .

doi: 10.1016/S1473-3099(21)00290-5 pubmed: 34171231 pmcid: 8219488

Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis. 2022;22:35–42. https://doi.org/10.1016/S1473-3099(21)00475-8 .

doi: 10.1016/S1473-3099(21)00475-8 pubmed: 34461056 pmcid: 8397301

Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021. https://doi.org/10.1136/bmj.n579 .

doi: 10.1136/bmj.n579 pubmed: 33687922

Davies NG, Jarvis CI, Group CC-W, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021. https://doi.org/10.1038/s41586-021-03426-1 .

doi: 10.1038/s41586-021-03426-1 pubmed: 34937049 pmcid: 8889665

Ong SWX, Chiew CJ, Ang LW, et al. Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta). Clin Infect Dis. 2022;75:e1128–36. https://doi.org/10.1093/cid/ciab721 .

doi: 10.1093/cid/ciab721 pubmed: 34423834

WHO Regional Office for Africa. Omicron spreads but severe cases remain low in South Africa. (2021). https://www.afro.who.int/news/omicron-spreads-severe-cases-remain-low-south-africa . Accessed 2023-02-05.

Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022;399:437–46. https://doi.org/10.1016/S0140-6736(22)00017-4 .

doi: 10.1016/S0140-6736(22)00017-4 pubmed: 35065011 pmcid: 8769664

Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet. 2022;399:1618–24. https://doi.org/10.1016/S0140-6736(22)00327-0 .

doi: 10.1016/S0140-6736(22)00327-0 pubmed: 35397851 pmcid: 8989396

Davies MA, Morden E, Rousseau P, et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province South Africa. Int J Infect Dis. 2023;127:63–8. https://doi.org/10.1016/j.ijid.2022.11.024 .

doi: 10.1016/j.ijid.2022.11.024 pubmed: 36436752 pmcid: 9686046

Houhamdi L, Gautret P, Hoang VT, Fournier PE, Colson P, Raoult D. Characteristics of the first 1119 SARS-CoV-2 Omicron variant cases, in Marseille, France, November-December 2021. J Med Virol. 2022;94:2290–5. https://doi.org/10.1002/jmv.27613 .

doi: 10.1002/jmv.27613 pubmed: 35060146 pmcid: 9015264

Maslo C, Toubkin M. Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave-Reply. JAMA. 2022;327:2148. https://doi.org/10.1001/jama.2022.5575 .

doi: 10.1001/jama.2022.5575 pubmed: 35670790

Ward IL, Bermingham C, Ayoubkhani D, et al. Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2) retrospective cohort study. BMJ. 2022. https://doi.org/10.1136/bmj-2022-070695 .

doi: 10.1136/bmj-2022-070695 pubmed: 36384890 pmcid: 10441183

Vihta KD, Pouwels KB, Peto TE, et al. Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom. Clin Infect Dis. 2022;76:e133–41. https://doi.org/10.1093/cid/ciac613 .

doi: 10.1093/cid/ciac613 pubmed: 35917440 pmcid: 9384604

Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. Condition WHOCCDWGoP-C-. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102–7. https://doi.org/10.1016/S1473-3099(21)00703-9 .

doi: 10.1016/S1473-3099(21)00703-9 pubmed: 34951953

World Health Organization (WHO). Post COVID-19 condition (Long COVID). 2023. https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition . Accessed 2023-11-17.

Ceban F, Ling S, Lui LMW, et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav Immun. 2022;101:93–135. https://doi.org/10.1016/j.bbi.2021.12.020 .

doi: 10.1016/j.bbi.2021.12.020 pubmed: 34973396

Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601–15. https://doi.org/10.1038/s41591-021-01283-z .

doi: 10.1038/s41591-021-01283-z pubmed: 33753937 pmcid: 8893149

Premraj L, Kannapadi NV, Briggs J, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis. J Neurol Sci. 2022. https://doi.org/10.1016/j.jns.2022.120162 .

doi: 10.1016/j.jns.2022.120162 pubmed: 35121209 pmcid: 8798975

Hayes LD, Ingram J, Sculthorpe NF. More Than 100 Persistent Symptoms of SARS-CoV-2 (Long COVID): A Scoping Review. Front Med (Lausanne). 2021. https://doi.org/10.3389/fmed.2021.750378 .

doi: 10.3389/fmed.2021.750378 pubmed: 34790680

Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis. 2022;226:1593–607. https://doi.org/10.1093/infdis/jiac136 .

doi: 10.1093/infdis/jiac136 pubmed: 35429399

Rochmawati E, Iskandar AC, Kamilah F. Persistent symptoms among post-COVID-19 survivors: A systematic review and meta-analysis. J Clin Nurs. 2022. https://doi.org/10.1111/jocn.16471 .

doi: 10.1111/jocn.16471 pubmed: 36426658

Fernandez-de-Las-Penas C, Nijs J, Neblett R, et al. Phenotyping Post-COVID Pain as a Nociceptive, Neuropathic, or Nociplastic Pain Condition. Biomedicines. 2022. https://doi.org/10.3390/biomedicines10102562 .

doi: 10.3390/biomedicines10102562 pubmed: 36289827 pmcid: 9599440

Tilch K, Hopff SM, Appel K, et al. Ethical and coordinative challenges in setting up a national cohort study during the COVID-19 pandemic in Germany. BMC Med Ethics. 2023;24:84. https://doi.org/10.1186/s12910-023-00959-0 .

doi: 10.1186/s12910-023-00959-0 pubmed: 37848886 pmcid: 10583323

Schons M, Pilgram L, Reese J-P, et al. The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics. Eur J Epidemiol. 2022. https://doi.org/10.1007/s10654-022-00896-z .

doi: 10.1007/s10654-022-00896-z pubmed: 35904671 pmcid: 9336157

Ludwig K, von der Schulenburg JM, Greiner W. German Value Set for the EQ-5D-5L. Pharmacoeconomics. 2018;36:663–74. https://doi.org/10.1007/s40273-018-0615-8 .

doi: 10.1007/s40273-018-0615-8 pubmed: 29460066 pmcid: 5954069

Grochtdreis T, Dams J, Konig HH, Konnopka A. Health-related quality of life measured with the EQ-5D-5L: estimation of normative index values based on a representative German population sample and value set. Eur J Health Econ. 2019;20:933–44. https://doi.org/10.1007/s10198-019-01054-1 .

doi: 10.1007/s10198-019-01054-1 pubmed: 31030292

RKI. Wöchentlicher Lagebericht des RKI zur Coronavirus-Krankheit-2019 (COVID-19) 03.02.2022—AKTUALISIERTER STAND FÜR DEUTSCHLAND. (2022). https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Wochenbericht/Wochenbericht_2022-02-03.pdf?__blob=publicationFile .

R Core Team. R: A language and environment for statistical computing, Vienna, Austria. (2021). https://www.R-project.org/ .

Kohls M, Miljukov O, Nürnberger C, Rainers M. epicodr: Primary coding for NAPKON data. (2023). https://github.com/nukleus-ecu/epicodr .

Fernandez-de-Las-Penas C, Notarte KI, Peligro PJ, et al. Long-COVID symptoms in individuals infected with different SARS-CoV-2 variants of concern: a systematic review of the literature. Viruses. 2022. https://doi.org/10.3390/v14122629 .

doi: 10.3390/v14122629 pubmed: 36560633 pmcid: 9785120

WHO Working group on the clinical characterisation and management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20:e192–7.

doi: 10.1016/S1473-3099(20)30483-7

Spinicci M, Graziani L, Tilli M, et al. Infection with SARS-CoV-2 variants is associated with different long COVID phenotypes. Viruses. 2022. https://doi.org/10.3390/v14112367 .

doi: 10.3390/v14112367 pubmed: 36366465 pmcid: 9698829

Fernandez-de-Las-Penas C, Cancela-Cilleruelo I, Rodriguez-Jimenez J, et al. Associated-onset symptoms and post-COVID-19 symptoms in hospitalized COVID-19 survivors infected with wuhan, alpha or delta SARS-CoV-2 variant. Pathogens. 2022. https://doi.org/10.3390/pathogens11070725 .

doi: 10.3390/pathogens11070725 pubmed: 36422588 pmcid: 9696487

Fernandez-de-Las-Penas C, Cancela-Cilleruelo I, Moro-Lopez-Menchero P, et al. Prevalence of musculoskeletal post-COVID pain in hospitalized COVID-19 survivors depending on infection with the historical, alpha or delta SARS-CoV-2 variant. Biomedicines. 2022. https://doi.org/10.3390/biomedicines10081951 .

doi: 10.3390/biomedicines10081951 pubmed: 36289827 pmcid: 9599440

Diexer S, Klee B, Gottschick C, et al. Association between virus variants, vaccination, previous infections, and post-COVID-19 risk. Int J Infect Dis. 2023;136:14–21. https://doi.org/10.1016/j.ijid.2023.08.019 .

doi: 10.1016/j.ijid.2023.08.019 pubmed: 37634619

Hedberg P, Naucler P. Post COVID-19 condition after SARS-CoV-2 infections during the omicron surge compared with the delta, alpha, and wild-type periods in Stockholm. Sweden J Infect Dis. 2023. https://doi.org/10.1093/infdis/jiad382 .

doi: 10.1093/infdis/jiad382

Karyakarte RP, Das R, Rajmane MV, et al. The burden and characteristics of Post-COVID-19 conditions among laboratory-confirmed delta and omicron COVID-19 cases: a preliminary study from Maharashtra, India. Cureus. 2023. https://doi.org/10.7759/cureus.44888 .

doi: 10.7759/cureus.44888 pubmed: 38090396 pmcid: 10711336

Thi Khanh HN, Cornelissen L, Castanares-Zapatero D, et al. Association between SARS-CoV-2 variants and post COVID-19 condition: findings from a longitudinal cohort study in the Belgian adult population. BMC Infect Dis. 2023;23:774. https://doi.org/10.1186/s12879-023-08787-8 .

doi: 10.1186/s12879-023-08787-8 pubmed: 37940843 pmcid: 10634063

Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399:2263–4. https://doi.org/10.1016/S0140-6736(22)00941-2 .

doi: 10.1016/S0140-6736(22)00941-2 pubmed: 35717982 pmcid: 9212672

Wise J. Covid-19: Long covid risk is lower with omicron than delta, researchers find. BMJ. 2022. https://doi.org/10.1136/bmj.o1500 .

doi: 10.1136/bmj.o1500 pubmed: 36740885

Hernandez-Aceituno A, Garcia-Hernandez A, Larumbe-Zabala E. COVID-19 long-term sequelae: omicron versus alpha and delta variants. Infect Dis Now. 2023. https://doi.org/10.1016/j.idnow.2023.104688 .

doi: 10.1016/j.idnow.2023.104688 pubmed: 36858287 pmcid: 9970656

Willan J, Agarwal G, Bienz N. Mortality and burden of post-COVID-19 syndrome have reduced with time across SARS-CoV-2 variants in haematology patients. Br J Haematol. 2023;201:640–4. https://doi.org/10.1111/bjh.18700 .

doi: 10.1111/bjh.18700 pubmed: 36861893

Ballouz T, Menges D, Kaufmann M, et al. Post COVID-19 condition after wildtype, delta, and omicron SARS-CoV-2 infection and prior vaccination: pooled analysis of two population-based cohorts. PLoS ONE. 2023. https://doi.org/10.1371/journal.pone.0281429 .

doi: 10.1371/journal.pone.0281429 pubmed: 36812215 pmcid: 9946205

Du M, Ma Y, Deng J, Liu M, Liu J. Comparison of long COVID-19 caused by different SARS-CoV-2 strains: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022. https://doi.org/10.3390/ijerph192316010 .

doi: 10.3390/ijerph192316010 pubmed: 36613066 pmcid: 9819847

Magnusson K, Kristoffersen DT, Dell’Isola A, et al. Post-covid medical complaints following infection with SARS-CoV-2 omicron vs delta variants. Nat Commun. 2022;13:7363. https://doi.org/10.1038/s41467-022-35240-2 .

doi: 10.1038/s41467-022-35240-2 pubmed: 36450749 pmcid: 9709355

Jassat W, Mudara C, Vika C, et al. A cohort study of post-COVID-19 condition across the beta, delta, and omicron waves in South Africa: 6-month follow-up of hospitalized and nonhospitalized participants. Int J Infect Dis. 2023;128:102–11. https://doi.org/10.1016/j.ijid.2022.12.036 .

doi: 10.1016/j.ijid.2022.12.036 pubmed: 36587841 pmcid: 9800016

Gottlieb M, Wang RC, Yu H, et al. Severe fatigue and persistent symptoms at 3 months following severe acute respiratory syndrome coronavirus 2 infections during the pre-delta, delta, and omicron time periods: a multicenter prospective cohort study. Clin Infect Dis. 2023;76:1930–41. https://doi.org/10.1093/cid/ciad045 .

doi: 10.1093/cid/ciad045 pubmed: 36705268 pmcid: 10249989

Percze AR, Nagy A, Polivka L, et al. Fatigue, sleepiness and sleep quality are SARS-CoV-2 variant independent in patients with long COVID symptoms. Inflammopharmacology. 2023. https://doi.org/10.1007/s10787-023-01190-4 .

doi: 10.1007/s10787-023-01190-4 pubmed: 37020055 pmcid: 10075170

Agergaard J, Gunst JD, Schiottz-Christensen B, Ostergaard L, Wejse C. Long-term prognosis at 1.5 years after Infection with Wild-type strain of SARS-CoV-2 and alpha, delta, as well as omicron variants. Int J Infect Dis. 2023. https://doi.org/10.1016/j.ijid.2023.10.022 .

doi: 10.1016/j.ijid.2023.10.022 pubmed: 37907167

Grupp H, Konig HH, Konnopka A. Health care utilisation and costs in the general population in Germany. Health Policy. 2016;120:159–69. https://doi.org/10.1016/j.healthpol.2015.11.005 .

doi: 10.1016/j.healthpol.2015.11.005 pubmed: 26797256